Post Reply
701-720 of 2521
Hosey...maybe 0.50 in the future
yamseng ( Date: 12-Jan-2022 23:12) Posted:
|
in the future, the company might introduce a saliva test kit for other diseases !!
get ready for tmr chiong....
calling HSA to approve .....then we will see 18 soon
get ready for tmr chiong....
calling HSA to approve .....then we will see 18 soon
tankoksee ( Date: 12-Jan-2022 22:20) Posted:
|
Expertise joined the company and 'To da moon' soon.. Ya, really need hold tight and not tempted to let go with small price jump...🚀 🚀 🚀 .
tankoksee ( Date: 12-Jan-2022 22:20) Posted:
|
watch out...
might be something much much bigger than the saliva testing kit...
more than that n more to come.......
might be something much much bigger than the saliva testing kit...
more than that n more to come.......
18 is very good but maybe go 108 better😁 🚀 🚀 🚀
yamseng ( Date: 12-Jan-2022 21:46) Posted:
|
Looks like very good stuffs ahead.... All parties got a 'pie' in DLL....... 👍
LowLow12 ( Date: 12-Jan-2022 21:42) Posted:
|
i q some at 8 to sell, but no taker till end of the day
think better keep it till the share price hit (1 plus 8) => 18 !! huat ah
think better keep it till the share price hit (1 plus 8) => 18 !! huat ah
tankoksee ( Date: 12-Jan-2022 16:04) Posted:
|
APPOINTMENT OF DIRECTOR AND CHANGE IN SHAREHOLDINGS AT DIGITAL LIFE LINE PTE. LTD., A SUBSIDIARY OF DISA DIGITAL SAFETY PTE. LTD.
Further to the announcement pertaining to the appointment of directors and change in shareholdings at Digital Life Line Pte. Ltd. (?DLL?) dated 29 December 2021, the board of directors (the ?Board?) of the Company wishes to announce the following:
(1) Dr. Chua Lee Kiang, Melvin will be appointed as the director of DLL with effect from 12 January 2022
Dr. Melvin Chua, who is also one of the inventors of the new saliva-based COVID-19 ART technology, is a Clinician-Scientist at the National Cancer Centre Singapore, and Principal Investigator of the Tan Chin Tuan Laboratory of Optical Imaging, Photodynamic and Proton Beam Therapy ? Precision Radiation Oncology Programme. He is also the Head of Department and Senior Consultant for Head and Neck and Thoracic Cancers, Division of Radiation Oncology and the Director of the Data and computational Science Core. His research is supported by the NMRC (National Medical Research Council) Clinician-scientist award, and is focused on discovery and translational cancer genomics, and the development of biomarker-directed clinical trials in nasopharyngeal (NPC) and prostate cancers.
He graduated from the Yong Loo Lin School of Medicine, National University Singapore in 2002. He obtained his Fellowship in Clinical Oncology from the Royal College of Radiologists, and his Doctorate from the University College London in 2013. He later completed post-doctoral Clinician- scientist fellowships at the Mount Vernon Cancer Centre, UK, and the Princess Margaret Cancer Center, Toronto. In 2021, he obtained his fellowship of the Academy of Medicine Singapore under the College of Radiation Oncology and Clinician Scientists.
Dr. Chua is a KOL (Key Opinion Leader) on NPC (Nasopharyngeal Carcinoma) and prostate cancer, and he has been invited to speak at more than 100 international meetings. He is also on the scientific advisory board for the NPC Guangzhou-Singapore Trial Network, a board member on the Head Neck Cancer International Group (HNCIG) and the Scientific Committee Chairman of HNCIG Artificial Intelligence working group.
Following the abovementioned appointment, with effect from 12 January 2022, the composition of the Board of DLL shall be as follows:
Professor Soo Khee Chee, Chairman Dr. Chua Lee Kiang, Melvin
Dr. Guy Heathers
Mr. John Wong Weng Foo
Mr. Chng Weng Wah, Managing Director and CEO Mr. Han Yang Kwang
Further to the announcement pertaining to the appointment of directors and change in shareholdings at Digital Life Line Pte. Ltd. (?DLL?) dated 29 December 2021, the board of directors (the ?Board?) of the Company wishes to announce the following:
(1) Dr. Chua Lee Kiang, Melvin will be appointed as the director of DLL with effect from 12 January 2022
Dr. Melvin Chua, who is also one of the inventors of the new saliva-based COVID-19 ART technology, is a Clinician-Scientist at the National Cancer Centre Singapore, and Principal Investigator of the Tan Chin Tuan Laboratory of Optical Imaging, Photodynamic and Proton Beam Therapy ? Precision Radiation Oncology Programme. He is also the Head of Department and Senior Consultant for Head and Neck and Thoracic Cancers, Division of Radiation Oncology and the Director of the Data and computational Science Core. His research is supported by the NMRC (National Medical Research Council) Clinician-scientist award, and is focused on discovery and translational cancer genomics, and the development of biomarker-directed clinical trials in nasopharyngeal (NPC) and prostate cancers.
He graduated from the Yong Loo Lin School of Medicine, National University Singapore in 2002. He obtained his Fellowship in Clinical Oncology from the Royal College of Radiologists, and his Doctorate from the University College London in 2013. He later completed post-doctoral Clinician- scientist fellowships at the Mount Vernon Cancer Centre, UK, and the Princess Margaret Cancer Center, Toronto. In 2021, he obtained his fellowship of the Academy of Medicine Singapore under the College of Radiation Oncology and Clinician Scientists.
Dr. Chua is a KOL (Key Opinion Leader) on NPC (Nasopharyngeal Carcinoma) and prostate cancer, and he has been invited to speak at more than 100 international meetings. He is also on the scientific advisory board for the NPC Guangzhou-Singapore Trial Network, a board member on the Head Neck Cancer International Group (HNCIG) and the Scientific Committee Chairman of HNCIG Artificial Intelligence working group.
Following the abovementioned appointment, with effect from 12 January 2022, the composition of the Board of DLL shall be as follows:
Professor Soo Khee Chee, Chairman Dr. Chua Lee Kiang, Melvin
Dr. Guy Heathers
Mr. John Wong Weng Foo
Mr. Chng Weng Wah, Managing Director and CEO Mr. Han Yang Kwang
Change - Change in Corporate Information::APPOINTMENT OF DIRECTOR AND CHANGE IN SHAREHOLDINGS AT DIGITAL LIFE LINE PTE. LTD....
https://links.sgx.com/1.0.0/corporate-announcements/KBVGVU6VG0GL71C6/697450_Appointment%20of%20Director%20and%20Change%20of%20Shareholdings.pdf
hope all buyers of 8 n 9 picked up their loading...
more to come after this consolidation...
more to come after this consolidation...
8 dec announced
Now only one month 3 days
HSA fast track approval also may need 2 months
Hence just nice maybe Chinese New Year rally on approval
Just b patient wait for ew5 at 12/13
Fingers and toes crossed
Now only one month 3 days
HSA fast track approval also may need 2 months
Hence just nice maybe Chinese New Year rally on approval
Just b patient wait for ew5 at 12/13
Fingers and toes crossed
OKAYCAN ( Date: 12-Jan-2022 08:41) Posted:
|
haha....just continue to load when funds arrived and put aside...No need see the very short term movement.....Fingers cross.....
OKAYCAN ( Date: 12-Jan-2022 08:41) Posted:
|
What is mid 15?
OKAYCAN ( Date: 12-Jan-2022 08:41) Posted:
|
I believe most who bought this know the fact that the kit will commercialised 4-6months, starting from mid 15. Of course subjected to hsa approval.
Basically be patience
Basically be patience
Bro
Very few done at 10
Only 600-700 lots
For the last one week majority traded
At 8-9
Hence, the base is 8
No matter how these ppl contra 8 or 9
If they have no money pick up
BBs will hope they sell back 7 or 8.
Not much impact at all these contras
Or scrapers
On hindsight
This is a good value to add more again
Wait for EW 5 which is 12/13
Huat Huat before cny come
Hopefully some more news then
Very few done at 10
Only 600-700 lots
For the last one week majority traded
At 8-9
Hence, the base is 8
No matter how these ppl contra 8 or 9
If they have no money pick up
BBs will hope they sell back 7 or 8.
Not much impact at all these contras
Or scrapers
On hindsight
This is a good value to add more again
Wait for EW 5 which is 12/13
Huat Huat before cny come
Hopefully some more news then
Sibehboeng ( Date: 11-Jan-2022 16:13) Posted:
|
I' m holding but also thinking wasted should have taken profit when it shot up and buy back now. But hindsight 20/20. I worry for those contrarers who chased up to 10. At this level, when due, will lose close to half.
LowLow12 ( Date: 11-Jan-2022 14:17) Posted:
|
Need 'Tong/Tong', can see good stuffs ahead.....😁 ... Hope bbs gap up the stock.... 🚀 🚀 🚀
Andrew123 ( Date: 11-Jan-2022 14:30) Posted:
|
Yes patient
LowLow12 ( Date: 11-Jan-2022 14:17) Posted:
|
Wave 4 touches 7
now 7/8 EW 4
Next should be 12/13 EW 5
Dont contra
Dont scrap
Buy and keep and will see EW 5 12/13
50pct upside from 8
quite good investment.
Cheers
now 7/8 EW 4
Next should be 12/13 EW 5
Dont contra
Dont scrap
Buy and keep and will see EW 5 12/13
50pct upside from 8
quite good investment.
Cheers
Normally such ultra penny stock once break 10, it will move very fast in few bids at a time
Today depth is weird
After 10, don?t really have big walls
The breakout is imminent
Anytime this week.
Looking good
Hope can close a good 12-15 by Friday
Cheers supporters
Today depth is weird
After 10, don?t really have big walls
The breakout is imminent
Anytime this week.
Looking good
Hope can close a good 12-15 by Friday
Cheers supporters